Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021.

Kissling, EstherHooiveld, MarietteSandonis Martín, VirginiaMartínez-Baz, IvánWilliam, NaomaVilcu, Ana-MariaMazagatos, ClaraDomegan, Lisade Lusignan, SimonMeijer, AdamMachado, AusendaBrytting, MiaCasado, ItziarMurray, Josephine-L KBelhillil, SylvieLarrauri, AmparoO'Donnell, JoanTsang, Rubyde Lange, MaritRodrigues, Ana PaulaRiess, MaximilianCastilla, JesúsHamilton, MarkFalchi, AlessandraPozo, FranciscoDunford, LindaCogdale, JadeJansen, TessaGuiomar, RaquelEnkirch, TheresaBurgui, CristinaSigerson, DebbieBlanchon, ThierryMartínez Ochoa, Eva MaríaConnell, JeffEllis, Joannavan Gageldonk-Lafeber, RianneKislaya, IrinaRose, Angela McValenciano, Marta2021-08-022021-08-023429667610.2807/1560-7917.ES.2021.26.29.2100670http://hdl.handle.net/10029/625207enCOVID-19EuropeSARS-CoV-2multicentre studytest-negative designvaccine effectivenessVaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021.Article1560-7917Euro Surveill 2021; 26(29):pii.2100670